BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

RayBiotech and Abeome Corporation Announce an Agreement Related to Novel Research Products for Ovarian Cancer


11/2/2012 9:26:21 AM

NORCROSS, Ga., Nov. 1, 2012 /PRNewswire/ -- RayBiotech, Inc. and Abeome Corporation today announced that the companies have entered into a collaboration whereby Abeome will provide over 300 novel monoclonal antibodies recognizing human ovarian cancer for use in the development of RayBiotech's antibody-related portfolio of products. These antibodies recognize ovarian cancer but not normal ovary tissue. Financial terms were not disclosed.

RayBiotech's President, Chief Operating Officer and Co-Founder, Rani Huang stated, "Ovarian cancer is a devastating disease and most often goes undetected until very late stages of progression. This alliance with Abeome will enable RayBiotech to provide products and services for the preclinical characterization of ovarian cancer-related biological samples. We are delighted to have entered into this agreement with another Georgia-based bioreagent company."

Abeome's President and CEO, Dr. Richard Shimkets said, "We are very pleased to be working with RayBiotech in providing key reagents for studying ovarian cancer. These antibodies, made with Abeome's patented DiSH technology, are the result of a unique direct immunization of mice with human ovarian cancer cells. It is our hope that their use will help define better diagnostic and therapeutic options for ovarian cancer patients."

About RayBiotech, Inc.

In 2001 RayBiotech (http://www.raybiotech.com) introduced the first commercially available cytokine antibody array. With a focus on translating scientific knowledge into improved health, RayBiotech continues to pioneer advances in high-throughput platforms for identifying disease mechanisms, screening and validation of biomarkers and identification of drug targets. RayBiotech products are featured in hundreds of publications, including: Nature, Nature Medicine, Cell, Lancet, PNAS and many others. Offering the largest selection of protein arrays, RayBiotech has established a reputation for high quality and innovation in the research community. A spin-off from Emory University, RayBiotech is privately owned, with headquarters in metropolitan Atlanta.

About Abeome Corporation

Abeome (www.abeomecorp.com) has developed and patented novel technology for the rapid discovery of high quality monoclonal antibodies, and manufactures kits and specialized growth media to allow researchers to use that technology in their own laboratories. To date Abeome has made over 2000 monoclonal antibodies, alone or in collaboration with numerous pharmaceutical and biotechnology companies, using its proprietary technologies. Abeome is based in Athens, Georgia.

About Ovarian Cancer

Approximately 22,000 women in the United States will develop ovarian cancer in 2012, 80% of which will not live more than 5 years after diagnosis. Ovarian cancer is very treatable if detected early, but limited screening options are available that can detect early-stage disease. In September of 2012, an expert panel of the United Stated Preventative Services Task Force concluded that existing diagnostic tests do more harm than good in screening healthy woman, as high false-positive results (~10%) lead to more than 1000 unnecessary surgeries per year, 15% of which have serious complications.

For More Information:

Rob Burgess, PhD
Director, Business Development
RayBiotech, Inc.
Phone: 770-729-2992
Email: rob@raybiotech.com

Richard Shimkets, PhD
President and CEO, Abeome Corporation
Phone: 706-542-7889
Email: rick.shimkets@abeomecorp.com

SOURCE RayBiotech, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES